宝济药业-B(02659)今日盘中股价大幅下挫5.03%，引发市场关注。
消息面上，公司早间发布公告，宣布其核心在研新药KJ103用于肾移植脱敏治疗的III期临床试验已完成所有入组受试者的主要随访，并将尽快向国家药监局提交新药上市申请。KJ103是一款全球首创的低免疫原性创新重组免疫球蛋白G降解酶，此前已获得突破性治疗药物认定。
然而，公司在同一公告中亦提示风险，明确指出无法保证KJ103最终能够成功开发或实现商业化，并提醒股东及潜在投资者在买卖公司股份时需审慎行事。市场分析认为，尽管新药研发取得阶段性进展，但商业化前景的不确定性引发了投资者的担忧，可能是导致股价盘中承压下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.